These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 36073212)

  • 1. [
    Xie Y; Li C; Zhang L; Zang S; Yu F; Wang S; Wang F
    Nan Fang Yi Ke Da Xue Xue Bao; 2022 Aug; 42(8):1143-1148. PubMed ID: 36073212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations of the
    Karyagar SS; Karyagar S; Guven O
    Hell J Nucl Med; 2020; 23(2):120-124. PubMed ID: 32716402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Schmidkonz C; Cordes M; Schmidt D; Bäuerle T; Goetz TI; Beck M; Prante O; Cavallaro A; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1862-1872. PubMed ID: 29725716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience.
    Okudan B; Coşkun N; Seven B; Atalay MA; Yildirim A; Görtan FA
    Nucl Med Commun; 2021 Nov; 42(11):1254-1260. PubMed ID: 34284438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
    Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlations of
    Topuz ÖV; Aksu A; Erinç SR; Tamam MÖ
    Hell J Nucl Med; 2021; 24(1):60-65. PubMed ID: 33866340
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of
    Zou Q; Jiao J; Zou MH; Li MZ; Yang T; Xu L; Zhang Y
    Abdom Radiol (NY); 2020 Dec; 45(12):4202-4213. PubMed ID: 32948911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of 68Ga-PSMA PET/CT with volumetric parameters for staging of prostate cancer patients.
    Aksu A; Karahan Şen NP; Tuna EB; Aslan G; Çapa Kaya G
    Nucl Med Commun; 2021 May; 42(5):503-509. PubMed ID: 33560717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
    Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
    Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI,
    Akkaya H; Dilek O; Özdemir S; Taş ZA; Öztürk İS; Gülek B
    Diagn Interv Radiol; 2023 Sep; 29(5):647-655. PubMed ID: 37395389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
    Ergül N; Yilmaz Güneş B; Yücetaş U; Toktaş MG; Çermik TF
    Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct Patlak Reconstruction of [
    Rasul S; Geist BK; Einspieler H; Fajkovic H; Shariat SF; Schmitl S; Mitterhauser M; Bartosch R; Langsteger W; Baltzer PAT; Beyer T; Ferrara D; Haug AR; Hacker M; Rausch I
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37761975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer.
    Meyrick DP; Asokendaran M; Skelly LA; Lenzo NP; Henderson A
    Nucl Med Commun; 2017 Nov; 38(11):956-963. PubMed ID: 28922335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment?
    Karyağar S; Güven O; Karyağar SS; Arici S; Selvi O; Geredeli Ç; Özülker F
    Nucl Med Commun; 2021 Sep; 42(9):1011-1016. PubMed ID: 33958536
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Vinsensia M; Chyoke PL; Hadaschik B; Holland-Letz T; Moltz J; Kopka K; Rauscher I; Mier W; Schwaiger M; Haberkorn U; Mauer T; Kratochwil C; Eiber M; Giesel FL
    J Nucl Med; 2017 Dec; 58(12):1949-1955. PubMed ID: 28637799
    [No Abstract]   [Full Text] [Related]  

  • 18. Retrospective correlation of
    Onal C; Torun N; Oymak E; Guler OC; Reyhan M; Yapar AF
    Ann Nucl Med; 2020 Jun; 34(6):388-396. PubMed ID: 32221791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial Experience with Volumetric
    Schmuck S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
    J Nucl Med; 2017 Dec; 58(12):1962-1968. PubMed ID: 28522740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlations between whole body volumetric parameters of
    Yildirim ÖA; Gündoğan C; Can C; Poyraz K; Erdur E; Kömek H
    Ann Nucl Med; 2021 May; 35(5):540-548. PubMed ID: 33586097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.